By offering deep discounts exclusively through select telehealth platforms, drugmakers create a powerful sales channel that may incentivize providers to preferentially prescribe their products. This arrangement raises ethical concerns that financial incentives could override independent medical judgment, potentially compromising patient care.

The US healthcare system is creating a major bottleneck for GLP-1s. While Medicare is beginning to cover the drugs for seniors, private insurers, who cover two-thirds of Americans, are simultaneously increasing hurdles and dropping coverage, effectively hitting the gas and brakes on a major public health tool.

A real-world case study shows how payer restrictions, not clinical judgment, can dictate cancer treatment. A patient was forced to switch from a well-tolerated drug (darolutamide) to another (apalutamide), which caused a rash, before the original, more suitable therapy could be re-justified and approved.

Eli Lilly and Novo Nordisk's DTC programs for weight loss drugs give employers an alternative to point employees towards, providing cover to drop expensive insurance coverage and potentially reducing access for patients who rely on it.

Dr. Smith highlights a critical flaw in pharmacology: while a single drug undergoes rigorous FDA testing, there is zero data on the interactive effects when a patient takes two or more drugs concurrently. This 'polypharmacy' creates unpredictable and potentially harmful side effects.

True innovation in getting drugs to patients is not about pharma creating pricing models alone. It requires a multi-stakeholder partnership where payers, physicians, and manufacturers work together to solve problems for specific patient subgroups. This collaborative effort, not a unilateral one, is what truly saves lives and reduces costs.

Pharma companies now partner with telehealth providers to offer coupons that reduce the cost of the physician consultation itself. This marketing tactic incentivizes patients to seek a prescription for a specific drug, raising questions about overprescribing and conflicts of interest.

A key commercial barrier for combination therapies is getting insurers to pay for two separate, expensive branded drugs. The winning strategy, outlined by Spire's CEO, is to develop co-formulated products sold as a single brand with one price. This avoids reimbursement complexities and presents a clearer value proposition to payers than stacking therapies.

Smaller biotech firms face significant hurdles in gaining market access. They often cannot negotiate directly with Pharmacy Benefit Managers (PBMs) for formulary placement. Instead, they must use a third-party negotiator representing multiple small companies, a process that is opaque and can cause critical launch delays.